How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs
2018 ◽
Vol 38
(1)
◽
pp. 181-209
◽
2018 ◽
Vol 54
(1)
◽
pp. 106-109
◽